Chemoembolization endpoints: Effect on survival among patients with hepatocellular carcinoma

American Journal of Roentgenology

Volumn 196, Issue 4, 2011, Pages 919-928

  Jin, Brian ^a   Wang, Dingxin ^a   Lewandowski, Robert J ^a   Riaz, Ahsun ^a   Ryu, Robert K ^a   Sato, Kent T ^a   Larson, Andrew C ^a   Salem, Riad ^a   Omary, Reed A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Embolization; Endpoint; Hepatocellular carcinoma; Survival; Transarterial chemoembolization

Indexed keywords

CISPLATIN; DOXORUBICIN; MITOMYCIN C;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR BLOOD FLOW; ANALYSIS OF VARIANCE; BIOASSAY; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

AGED; ANALYSIS OF VARIANCE; ANGIOGRAPHY, DIGITAL SUBTRACTION; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; ENDPOINT DETERMINATION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 79957859250     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.4770     Document Type: Article

References (29)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogene- sis. Gastroenterology 2007; 132:2557-2576 (Pubitemid 46890874)
2. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35:519-524 (Pubitemid 34183954)
3. Trinchet JC, Beaugrand M. Treatment of hepatocellular carcinoma in patients with cirrhosis. J Hepatol 1997; 27:756-765 (Pubitemid 27448761)
4. Marcos-Alvarez A, Jenkins RL, Washburn WK, et al. Multimodality treatment of hepatocellular carcinoma in a hepatobiliary specialty center. Arch Surg 1996; 131:292-298 (Pubitemid 26078816)
5. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-1739 (Pubitemid 34607087)
6. Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 2009; 20:S317-S323
7. Coldwell DM, Stokes KR, Yakes WF. Embolotherapy: agents, clinical applications, and techniques. Radiographics 1994;14:623-643
8. Brown DB, Pilgram TK, Darcy MD, et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 2005; 16:1661-1666 (Pubitemid 44431163)
9. Ikeda M, Maeda S, Shibata J, et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 2004; 66:24-31 (Pubitemid 38410676)
10. Maeda S, Fujiyama S, Tanaka M, Ashihara H, Hirata R, Tomita K. Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization. Hepatol Res 2002; 23:202-210 (Pubitemid 36104399)
11. Geschwind JF, Ramsey DE, Cleffken B, et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 2003; 26:111-117 (Pubitemid 36919549)
12. Kobayashi N, Ishii M, Ueno Y, et al. Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization. Liver 1999; 19:25-31 (Pubitemid 29034107)
13. Xiong ZP, Yang SR, Liang ZY, et al. Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2004; 3:386-390
14. Rhee TK, Young JY, Larson AC, et al. Effect of transcatheter arterial embolization on levels of hypoxia-inducible factor-1alpha in rabbit VX2 liver tumors. J Vasc Interv Radiol 2007; 18:639-645 (Pubitemid 46661178)
15. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430 (Pubitemid 32844200)
16. Lewandowski RJ, Wang D, Gehl J, et al. A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion/MR imaging monitoring. J Vasc Interv Radiol 2007; 18:1249-1257 (Pubitemid 47449750)
17. Greene FL; American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging handbook: from the AJCC cancer staging manual, 6th ed. New York, NY: Springer-Verlag, 2002
18. [No authors listed]. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28:751-755
19. Kim YB, Park YN, Park C. Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology 2001; 38:160-166 (Pubitemid 32193630)
20. Poon RT, Lau C, Yu WC, Fan ST, Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 2004; 11:1077-1084
21. Simonetti RG, Camma C, Fiorello F, Politi F, D'Amico G, Pagliaro L. Hepatocellular carcinoma: a worldwide problem and the major risk factors. Dig Dis Sci 1991; 36:962-972
22. Virmani S, Ryu RK, Sato KT, et al. Effect of Carm angiographic CT on transcatheter arterial chemoembolization of liver tumors. J Vasc Interv Radiol 2007; 18:1305-1309 (Pubitemid 47446273)
23. Wallace MJ, Murthy R, Kamat PP, et al. Impact of C-arm CT on hepatic arterial interventions for hepatic malignancies. J Vasc Interv Radiol 2007; 18:1500-1507 (Pubitemid 350151867)
24. Wang D, Jin B, Lewandowski RJ, et al. Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma. J Magn Reson Imaging 2010; 31:1106-1116
25. Larson AC, Wang D, Atassi B, et al. Transcatheter intraarterial perfusion: MR monitoring of chemoembolization for hepatocellular carcinoma - feasibility of initial clinical translation. Radiology 2008; 246:964-971
26. Graziadei IW, Sandmueller H, Waldenberger P, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9:557-563 (Pubitemid 36701690)
27. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005; 11:767-775 (Pubitemid 40975578)
28. Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12:1260-1267 (Pubitemid 44194595)
29. Gaba RC, Wang D, Lewandowski RJ, et al. Fourdimensional transcatheter intraarterial perfusion MR imaging for monitoring chemoembolization of hepatocellular carcinoma: preliminary results. J Vasc Interv Radiol 2008; 19:1589-1595